HC Wainwright Forecasts PolyPid’s Q1 Earnings (NASDAQ:PYPD)

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for PolyPid in a report issued on Monday, April 14th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.16) EPS.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23).

Several other brokerages also recently commented on PYPD. Rodman & Renshaw assumed coverage on PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price target on the stock. RODMAN&RENSHAW upgraded shares of PolyPid to a “strong-buy” rating in a research note on Tuesday, January 28th.

PolyPid Stock Performance

NASDAQ:PYPD opened at $2.55 on Tuesday. The firm has a market capitalization of $25.99 million, a PE ratio of -0.51 and a beta of 1.28. PolyPid has a 1 year low of $2.30 and a 1 year high of $5.09. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08. The firm’s fifty day simple moving average is $2.83 and its 200 day simple moving average is $3.10.

Institutional Investors Weigh In On PolyPid

Institutional investors and hedge funds have recently bought and sold shares of the business. J. Goldman & Co LP acquired a new position in shares of PolyPid in the 4th quarter worth approximately $391,000. AIGH Capital Management LLC grew its position in PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after acquiring an additional 148,199 shares during the period. Finally, Rosalind Advisors Inc. grew its position in PolyPid by 49.9% in the fourth quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after acquiring an additional 338,853 shares during the period. Institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.